UChicago Medicine recognized as America's Best Hospital in three categories by Newsweek
UChicago Medicine and its Comer Children's Hospital have both been recognized by Newsweek as top-ranked hospitals in the magazine's America’s Best Hospitals lists for 2023, including recognition on the lists for best cancer hospitals, best maternity hospitals and best children’s hospitals.
Apalutamide/ADT Shows PFS Improvement in Relapsed Prostate Cancer
Apalutamide plus androgen deprivation therapy (ADT) yielded a progression-free survival of 24.5 months vs 21.0 months with ADT alone.
pCR Rates Following Neoadjuvant Therapy Similar Between Black and White Women With Breast Cancer
Findings from a breast cancer analysis demonstrated that pathologic complete response and event-free survival rates were not significantly affected by patient’s race.
Merry and Bright: Bringing a Festive Air into the Oncology Space for the Holidays
In this episode of “The Vitals,” 2 health care professionals discuss how to safely celebrate the holidays in oncology units.
Myeloproliferative Neoplasms in Accelerated Phase Continue to Present as Treatment Challenge
Treating patients with myeloproliferative neoplasms in accelerated phase (MPN-AP) remains an ongoing challenge as there are still no standard therapeutic approaches, says an expert.
Personalized Screenings are Needed to Address Racial Disparities in Breast Cancer Outcomes
“We want to make sure we can provide the right treatment for the right patient at the right time,” says Olufunmilayo I. Olopade, MD, FACP, OON.
More Immunotherapy May Enter TNBC Space
Nearly 1 year following the first checkpoint inhibitor approval in advanced triple-negative breast cancer, additional immunotherapeutic agents are poised to enter the field, according to Rita Nanda, MD.
Moving Forward with PARP Inhibitors in Ovarian Cancer
The treatment landscape of ovarian cancer continues to change with the recent approvals of new agents.
Frontline Olaparib Plus Abiraterone Provides Consistent Clinical Benefit in HRR-Mutated mCRPC
Assessing Subsequent Therapies in mHSPC Confirms OS Benefit From Darolutamide
Long-term Regorafenib Remission in mCRC May Be Linked to ECOG Score, Less Advanced Disease
Abiraterone Plus Prednisone, Apalutamide Improves Prostate Cancer Outcomes Without Impacting HRQoL
2 Commerce Drive Cranbury, NJ 08512